Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

  • participants needed
  • sponsor
    Rigel Pharmaceuticals
Updated on 10 August 2022
respiratory failure
diagnostic procedures


The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.


The primary objective of this study is:

To evaluate the efficacy of fostamatinib when used in combination with standard of care (SOC) in subjects hospitalized with COVID-19 without respiratory failure and with certain high risk prognostic factors, as measured by the change in clinical status score.

Condition SARS coronavirus, Severe Acute Respiratory Syndrome, Lung Disease, severe acute respiratory syndrome (sars), Viral pneumonia, pneumonitis, SARS Pneumonia, sars, COVID19, lung inflammation, Throat and Tonsil Infections, Pulmonary Disease, Pneumonia (Pediatric), SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Upper respiratory infection, pneumoniae, Pneumonia
Treatment Placebo, fostamatinib
Clinical Study IdentifierNCT04629703
SponsorRigel Pharmaceuticals
Last Modified on10 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note